1.
Ciapponi A, Bardach A, Colaci C, Rodríguez Cairoli F, Argento F, Korbenfeld E, et al. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis. Rev Peru Med Exp Salud Publica [Internet]. 2024 Mar. 27 [cited 2024 Apr. 15];41(1):7-18. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/13351